An avian cell line designed for production of highly attenuated viruses (Q39906835)

15 September 2017

title

An avian cell line designed for production of highly attenuated viruses (English)

1 reference

15 September 2017

0 references

1

1 reference

15 September 2017

Ad Vos

2

1 reference

15 September 2017

Stefanie Beilfuss

3

1 reference

15 September 2017

Andreas Neubert

4

1 reference

15 September 2017

Sabine Breul

5

1 reference

15 September 2017

Volker Sandig

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

9 December 2008

1 reference

15 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

15 September 2017

volume

27

1 reference

15 September 2017

issue

5

1 reference

15 September 2017

page(s)

748-756

1 reference

describes a project that uses

15 September 2017

0 references

0 references

0 references

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Smallpox vaccination and bioterrorism with pox viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Detectionof reverse transcriptase activity in live attenuated virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Signaling networks that link cell proliferation and cell fate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus-5 E1A: paradox and paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Activation of adenoviral gene expression by protein IX is not required for efficient virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Analysis and prediction of leucine-rich nuclear export signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

NF-kappaB and virus infection: who controls whom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Activation of heat-shock response by an adenovirus is essential for virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Molecular chaperone Hsp90 is important for vaccinia virus growth in cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

The assembly of progesterone receptor-hsp90 complexes using purified proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Hsp90 as a capacitor of phenotypic variation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

inferred from DOI database lookup

7 January 2021

based on heuristic

The product of the adenovirus intermediate gene IX is a transcriptional activator.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.11.066

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.11.066

1 reference

15 September 2017

1 reference